NRG-GY019
SCHEMA



3. PATIENT SELECTION, ELIGIBILITY, AND INELIGIBILTY CRITERIA

Note: Per NCI guidelines, exceptions to inclusion and exclusion criteria are not permitted. For questions concerning eligibility, please contact the Biostatistical/Data Management Center (via the contact list on the NRG web site).

3.1 Patient Selection Guidelines

Although the guidelines provided below are not inclusion/exclusion criteria, investigators should consider these factors when selecting patients for this trial. Investigators also should consider all other relevant factors (medical and non-medical), as well as the risks and benefits of the study therapy, when deciding if a patient is an appropriate candidate for this trial.

3.1.1 Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up.

3.1.2 All women will, by definition, be considered menopausal due to surgical removal of both ovaries prior to trial enrollment.

3.2 Eligibility Criteria

A patient cannot be considered eligible for this study unless ALL of the following conditions are met.

3.2.1 Patients must have newly diagnosed, Stage II-IV low-grade serous carcinoma (invasive micropapillary serous carcinoma or invasive grade I serous carcinoma) of the ovary or peritoneum. Tumors must be assessed for nuclear p53 staining.

3.2.2 Appropriate stage for study entry based on the following diagnostic workup:

- History/physical examination within 14 days prior to registration;
- Contrast-enhanced Imaging of the chest, abdomen and pelvis within 28 days prior to registration;

3.2.3 Age ≥ 18

3.2.4 Patients must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (<1 cm diameter residual disease/nodule) or suboptimal residual disease (>1 cm diameter residual disease/nodule) status allowed.

3.2.5 Patients must have undergone a bilateral salpingo-oophorectomy

3.2.6 Patients must have an ECOG Performance Status of 0, 1 or 2 within 14 days prior to registration;

3.2.7 Patients must be within ≤8 weeks of primary cytoreductive surgery prior to initial randomization.

3.2.8 Patients must be able to take per oral (P.O.) medications.

3.2.9 Patients must have adequate organ and marrow function as defined below: NOTE: Institutional/laboratory upper limit of normal = ULN Institutional/laboratory lower limit of normal = LLN.

3.2.10 Bone marrow function within 14 days prior to registration defined as follows:

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
- Platelets greater than or equal to 100,000 cells/mcl

3.2.11 Adequate renal function within 14 days prior to registration defined as follows:

- Creatinine less than or equal to 1.5 x ULN -

- Patients whose serum creatinine is between 1.5 and 1.9 mg/dL are eligible if there is no hydronephrosis and the estimated creatinine clearance (CCr) is ≥ 30 ml/min. Please see Appendix VI for details.

3.2.12 Adequate hepatic function within 14 days prior to registration defined as follows:

- Bilirubin less than or equal to 1.5 x ULN
- ALT and AST less than or equal to 3 x ULN
- Alkaline phosphatase less than or equal to 2.5 x ULN

3.2.13 The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.

3.3 Ineligibility Criteria

Patients with any of the following conditions are NOT eligible for this study.

3.3.1 Patients with concomitant invasive malignancy or a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the past five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol.

3.3.2 Patients may not have received neoadjuvant chemotherapy or radiotherapy for the treatment of this disease.

3.3.3 Patients may not have received previous hormonal therapy for the treatment of this disease.

3.3.4 Patients with known hypersensitivity to letrozole or hypersensitivity/intolerance to carboplatin/paclitaxel therapy.

3.3.5 Patients with severe cardiac disease

- Myocardial infarction or unstable angina within 6 months prior to registration.
- New York Heart Association (NYHA) Class II or greater congestive heart failure.

3.3.6 Patients with known central nervous system metastases

3.3.7 Patients with active or uncontrolled systemic infection.

3.3.8 Patients with ≥grade 2 baseline neuropathy

3.3.9 HIV positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.